<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0010">
 <label>Table 2</label>
 <caption>
  <p>Clinical trials of the various therapeutics for COVID-19.</p>
 </caption>
 <alt-text id="al0040">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Sr. no.</th>
    <th>Therapeutic moiety/combinations</th>
    <th>Phase of clinical trial</th>
    <th>Route of administration</th>
    <th>Category and purpose in COVID-19</th>
    <th>Sponsor</th>
    <th>
     <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="ir0005" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> identifier
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="char">1</td>
    <td>Chloroquine</td>
    <td>2 &amp; 3, 4, 2</td>
    <td>Oral route</td>
    <td>Antimalarial, to treat mild Symptomatic and Asymptomatic cases of COVID-19</td>
    <td>HaEmek Medical Center, Israel, Wroclaw Medical University, Poland, Oxford University Clinical Research Unit, Vietnam</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04333628" id="ir0010" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04333628</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04331600" id="ir0015" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04331600</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04328493" id="ir0020" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04328493</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">2</td>
    <td>Hydroxychloroquine</td>
    <td>3, 3, 2, 2, 2</td>
    <td>Oral route</td>
    <td>Antimalarial, to prevent severe COVID-19 disease</td>
    <td>Dr. Michael Hill, University of Calgary, Canada, Germany, United States, Baylor University Medical Center, United States, California, Rambam Health Care Campus</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04329611" id="ir0025" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04329611</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04340544" id="ir0030" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04340544</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04329923" id="ir0035" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04329923</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04333225" id="ir0040" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04333225</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04335084" id="ir0045" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04335084</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04323631" id="ir0050" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04323631</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">3</td>
    <td>Remdesivir</td>
    <td>3</td>
    <td>I.V infusion</td>
    <td>Antiviral in treatment of COVID-19</td>
    <td>Gilead Sciences,</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04292899" id="ir0055" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04292899</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04292730" id="ir0060" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04292730</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">4</td>
    <td>Azithromycin</td>
    <td>3</td>
    <td>Oral route</td>
    <td>Antibiotic, to prevent COVD-19 disease progression</td>
    <td>University of California, San Francisco</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04332107" id="ir0065" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04332107</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">5</td>
    <td>Atovaquone/Azithromycin</td>
    <td>NA</td>
    <td>Oral route</td>
    <td>Anti-Malarial/Anti-Infective Combination to treat COVID-19 patients</td>
    <td>HonorHealth Research Institute, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04339426" id="ir0070" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04339426</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">6</td>
    <td>Lopinavir/ritonavir</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Antiretroviral, to treat COVID-19 patients</td>
    <td>Sunnybrook Health Sciences Centre, Canada</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04330690" id="ir0075" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04330690</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">7</td>
    <td>Lopinavir/ritonavir vs Hydroxychloroquine sulfate</td>
    <td>2</td>
    <td>Oral route</td>
    <td>To treat Mild COVID-19</td>
    <td>Asan Medical Center, Korea</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04307693" id="ir0080" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04307693</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">8</td>
    <td>
     <list list-type="simple" id="l0005">
      <list-item id="li0005">
       <label>1.</label>
       <p id="p0005">Lopinavir/ritonavir</p>
      </list-item>
      <list-item id="li0010">
       <label>2.</label>
       <p id="p0010">Hydroxychloroquine sulfate,</p>
      </list-item>
      <list-item id="li0015">
       <label>3.</label>
       <p id="p0015">Baricitinib,</p>
      </list-item>
      <list-item id="li0020">
       <label>4.</label>
       <p id="p0020">Sarilumab.</p>
      </list-item>
     </list>
    </td>
    <td>2</td>
    <td>1, 2, &amp; 3 Oral route, 4. S.C injection</td>
    <td>To treat moderate to severe COVID-19</td>
    <td>Lisa Barrett, Canada</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04321993" id="ir0085" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04321993</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">9</td>
    <td>Remdesivir, Lopinavir/ritonavir, interferon β-1A, and hydroxychloroquine</td>
    <td>3</td>
    <td>I.V infusion, oral route, S.C injection, and oral route respectively</td>
    <td>To treat COVID-19 patients</td>
    <td>National Institute of Health and Medical Research, France</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04315948" id="ir0090" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04315948</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">10</td>
    <td>Hydroxychloroquine, Oseltamivir, Azithromycin</td>
    <td>3</td>
    <td>Oral route</td>
    <td>To treat COVID-19 patients</td>
    <td>Shehnoor Azhar, Pakistan</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04338698" id="ir0095" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04338698</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">11</td>
    <td>Hydroxychloroquine and Nitazoxanide</td>
    <td>2, 3</td>
    <td>Oral route</td>
    <td>To evaluate safety and efficacy in COVID-19 patients</td>
    <td>Tanta University</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04361318" id="ir0100" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04361318</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">12</td>
    <td>Hydroxychloroquine vs. Azithromycin</td>
    <td>2, 3</td>
    <td>Oral route</td>
    <td>To treat COVID-19 patients</td>
    <td>Intermountain Health Care, Inc., United States, Intermountain Medical Center, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04329832" id="ir0105" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04329832</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04334382" id="ir0110" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04334382</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">13</td>
    <td>1. Lopinavir/ritonavir,
     <break/>2. Ribavirin and
     <break/>3. Interferon beta-1b
    </td>
    <td>2</td>
    <td>1 &amp; 2 oral route, 3 S.C injection</td>
    <td>To treat COVID-19 patients</td>
    <td>The University of Hong Kong, Hong Kong</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04276688" id="ir0115" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04276688</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">14</td>
    <td>Clevudine</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Antiviral, to evaluate safety and efficacy in COVID-19 patients</td>
    <td>Bukwang Pharmaceutical, Korea</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04347915" id="ir0120" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04347915</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">15</td>
    <td>Arbidol</td>
    <td>4</td>
    <td>Oral route</td>
    <td>Antiviral, to treat patients with COVID-19 pneumonia</td>
    <td>Jieming QU, Ruijin Hospital, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04260594" id="ir0125" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04260594</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">16</td>
    <td>Isotretinoin</td>
    <td>3</td>
    <td>Oral route</td>
    <td>Retinoid, to evaluate the safety and efficacy in COVID-19</td>
    <td>Tanta University, Egypt</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04361422" id="ir0130" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04361422</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">17</td>
    <td>Ivermectin and Nitazoxanide</td>
    <td>2, 3</td>
    <td>Oral route</td>
    <td>To evaluate the safety and efficacy of the combination in COVID-19</td>
    <td>Tanta University, Egypt</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04360356" id="ir0135" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04360356</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">18</td>
    <td>Recombinant human Interferon α1β</td>
    <td>1</td>
    <td>Nebulization</td>
    <td>To treat COVID-19 patients</td>
    <td>Tongji Hospital, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04293887" id="ir0140" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04293887</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">19</td>
    <td>
     <list list-type="simple" id="l0010">
      <list-item id="li0025">
       <label>1.</label>
       <p id="p0025">Bromhexine hydrochloride,</p>
      </list-item>
      <list-item id="li0030">
       <label>2.</label>
       <p id="p0030">Arbidol hydrochloride and 3. Recombinant Human-Interferon α2b</p>
      </list-item>
     </list>
    </td>
    <td>NA</td>
    <td>1 &amp; 2 oral route, 3 spray</td>
    <td>To treat patients with COVID-19 pneumonia</td>
    <td>Second Affiliated Hospital of Wenzhou Medical University, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04273763" id="ir0145" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04273763</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">20</td>
    <td>Deferoxamine</td>
    <td>1 &amp; 2</td>
    <td>Intravenous infusion</td>
    <td>Iron chelator, to reduce the Severity of COVID-19 Manifestations</td>
    <td>Kermanshah University of Medical Sciences, Iran</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04333550" id="ir0150" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04333550</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">21</td>
    <td>Dexamethasone</td>
    <td>4</td>
    <td>I.V</td>
    <td>Steroid, to treat patients with ARDS caused by COVID-19</td>
    <td>Dr. Negrin University Hospital, Spain</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04325061" id="ir0155" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04325061</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">22</td>
    <td>Piclidenoson</td>
    <td>2</td>
    <td>Oral route</td>
    <td>A3 adenosine receptor agonist, to treat COVID-19 patients</td>
    <td>Can-Fite BioPharma, Israel</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04333472" id="ir0160" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04333472</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">23</td>
    <td>Favipiravir</td>
    <td>3</td>
    <td>Oral route</td>
    <td>Antiviral, to evaluate safety and efficacy in COVID-19 patients</td>
    <td>Giuliano Rizzardini, Italy</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336904" id="ir0165" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336904</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">24</td>
    <td>Huaier Granule</td>
    <td>2 &amp; 3</td>
    <td>Oral route</td>
    <td>Adjuvant treatment of COVID-19</td>
    <td>Tongji Hospital, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04291053" id="ir0170" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04291053</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">25</td>
    <td>Tranexamic acid</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Antifibrinolytics, to study its effect on COVID-19</td>
    <td>The University of Alabama at Birmingham, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04338126" id="ir0175" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04338126</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">26</td>
    <td>BLD-2660</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Antiviral small molecule, to treat COVID-19</td>
    <td>Blade Therapeutics, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04334460" id="ir0180" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04334460</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">27</td>
    <td>Sildenafil citrate</td>
    <td>3</td>
    <td>Oral route</td>
    <td>Phosphodiesterase inhibitor, to treat COVID-19 patients</td>
    <td>Tongji Hospital, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04304313" id="ir0185" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04304313</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">28</td>
    <td>Losartan</td>
    <td>1</td>
    <td>Oral route</td>
    <td>Angiotensin receptor blocker, to treat respiratory failure due to COVID-19</td>
    <td>University of Kansas Medical Center, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04335123" id="ir0190" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04335123</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">29</td>
    <td>Telmisartan</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Angiotensin receptor blocker, to evaluate the efficacy in COVID-19 patients</td>
    <td>Laboratorio Elea Phoenix S.A., Argentina</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04355936" id="ir0195" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04355936</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">30</td>
    <td>Atorvastatin</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Statin, to assess the efficacy in reducing the deteroration of COVID-19 patients</td>
    <td>Mount Auburn Hospital</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04380402" id="ir0200" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04380402</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">31</td>
    <td>Prazosin</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Alpha-blockers, to evaluate the safety and efficacy of drug to prevent cytokine storm</td>
    <td>Johns Hopkins University, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04365257" id="ir0205" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04365257</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">32</td>
    <td>Chlorpromazine</td>
    <td>3</td>
    <td>Oral route</td>
    <td>Antipsychotics, to repurpose the drug for COVID-19 treatment</td>
    <td>Centre Hospitalier St Anne, France</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04366739" id="ir0210" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04366739</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">33</td>
    <td>Lenalidomide</td>
    <td>4</td>
    <td>Oral route</td>
    <td>Antiangiogenic agent, to treat mild to moderate COVID-19 patients</td>
    <td>Getafe University Hospital, Spain</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04361643" id="ir0215" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04361643</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">34</td>
    <td>FT516 - induced pluripotent stem cell</td>
    <td>1</td>
    <td>–</td>
    <td>To identify the maximum tolerated dose for the treatment of COVID-19</td>
    <td>Masonic Cancer Center, University of Minnesota</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04363346" id="ir0220" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04363346</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">35</td>
    <td>Allogeneic Mesenchymal Stromal Cells</td>
    <td>2</td>
    <td>I.V injection</td>
    <td>To evaluate safety and efficacy of cells in patients with COVID-19 Pneumonia</td>
    <td>Cell Therapy Network, Spain</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04361942" id="ir0225" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04361942</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">36</td>
    <td>Human Mesenchymal Stem Cells</td>
    <td>1 &amp; 2</td>
    <td>I.V</td>
    <td>Improve immune factor and to treat patients with COVID-19 pneumonia</td>
    <td>Puren Hospital, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04339660" id="ir0230" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04339660</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">37</td>
    <td>Anti-SARS-CoV-2 convalescent plasma</td>
    <td>2</td>
    <td>I.V infusion</td>
    <td>To assess the safety and efficacy</td>
    <td>Medical College of Wisconsin, Hackensack Meridian Health, United States, Joakim Dillner, Sweden</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04354831" id="ir0235" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04354831</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04343755" id="ir0240" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04343755</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04390178" id="ir0245" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04390178</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04384497" id="ir0250" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04384497</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">38</td>
    <td>Anti-SARS-CoV-2 convalescent plasma</td>
    <td>3</td>
    <td>I.V infusion</td>
    <td>To evaluate the efficacy</td>
    <td>Central Directorate of the Army Health Service, France,
     <break/>National Institute of Medical Sciences and Nutrition Salvador Zubiran, United Mexican States
    </td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04372979" id="ir0255" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04372979</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04388410" id="ir0260" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04388410</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">39</td>
    <td>Hyperimmune plasma with standard therapy</td>
    <td>2 &amp; 3</td>
    <td>I.V</td>
    <td>To evaluate safety and efficacy in COVID-19 patients</td>
    <td>University of Catanzaro, Italy</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04385043" id="ir0265" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04385043</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">40</td>
    <td>bac-TRL-Spike</td>
    <td>1</td>
    <td>Oral route</td>
    <td>To prevent COVID-19 in Healthy adults</td>
    <td>Symvivo Corporation, Canada</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04334980" id="ir0270" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04334980</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">41</td>
    <td>IFX-1 with Best supportive care</td>
    <td>2 &amp; 3</td>
    <td>I.V</td>
    <td>C5a antibody, to treat pneumonia.</td>
    <td>InflaRx GmbH, Netherlands</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04333420" id="ir0275" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04333420</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">42</td>
    <td>Acalabrutinib with Best supportive care</td>
    <td>2</td>
    <td>Oral route</td>
    <td>Bruton's tyrosine kinase inhibitor, To evaluate safety, efficacy and pharmacokinetics</td>
    <td>AstraZeneca, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04380688" id="ir0280" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04380688</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04346199" id="ir0285" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04346199</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">43</td>
    <td>Baricitinib</td>
    <td>2 &amp; 3</td>
    <td>I.V</td>
    <td>Janus Kinase inhibitor, to treat COVID-19</td>
    <td>University of Colorado, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04340232" id="ir0290" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04340232</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">44</td>
    <td>Tocilizumab</td>
    <td>2</td>
    <td>I.V injection</td>
    <td>Immunosuppressive, to treat patients with COVID-19 pneumonia</td>
    <td>National Cancer Institute, Naples, University Hospital Inselspital, Berne, Switzerland</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04317092" id="ir0295" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04317092</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04335071" id="ir0300" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04335071</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">45</td>
    <td>Canakinumab</td>
    <td>3</td>
    <td>I.V infusion</td>
    <td>Anti-human-IL-1β monoclonal antibody, To study the safety and efficacy in COVID-19 patients with cytokine release syndrome</td>
    <td>Novartis Pharmaceuticals, United States</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04362813" id="ir0305" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04362813</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">46</td>
    <td>Ruxolitinib</td>
    <td>2</td>
    <td>–</td>
    <td>Kinase inhibitor, to treat hyper inflammation in patients with stage II/III COVID-19</td>
    <td>Dr. Andreas Hochhaus, Germany</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04338958" id="ir0310" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04338958</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">47</td>
    <td>Ruxolitinib</td>
    <td>3</td>
    <td>Oral route</td>
    <td>To evaluate safety and efficacy in COVID-19 patients with Cytokine storm</td>
    <td>Novartis Pharmaceuticals, United Kingdom</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04362137" id="ir0315" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04362137</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">48</td>
    <td>BCG vaccine</td>
    <td>3</td>
    <td>Intracutaneous injection</td>
    <td>To reduce Health Care Workers Absenteeism in COVID-19</td>
    <td>UMC Utrecht, Netherlands, Murdoch Children Research Institute, Australia</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04328441" id="ir0320" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04328441</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04327206" id="ir0325" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04327206</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">49</td>
    <td>Artificial Antigen Presenting Cell (aAPC) Vaccine</td>
    <td>1</td>
    <td>S.C injection</td>
    <td>To treat COVID-19</td>
    <td>Shenzhen Geno-Immune Medical Institute, China</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04299724" id="ir0330" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04299724</ext-link>
    </td>
   </tr>
   <tr>
    <td align="char">50</td>
    <td>ChAdOx1 nCoV-19 Vaccine</td>
    <td>1 &amp; 2</td>
    <td>I.M</td>
    <td>To treat COVID-19</td>
    <td>University of Oxford, United Kingdom</td>
    <td>
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324606" id="ir0335" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04324606</ext-link>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
